Evogene Ltd has a consensus price target of $6.96 based on the ratings of 4 analysts. The high is $12 issued by Lake Street on August 23, 2024. The low is $1.85 issued by Alliance Global Partners on October 2, 2023. The 3 most-recent analyst ratings were released by Lake Street, Alliance Global Partners, and Lake Street on August 23, 2024, October 2, 2023, and August 18, 2023, respectively. With an average price target of $5.62 between Lake Street, Alliance Global Partners, and Lake Street, there's an implied 284.83% upside for Evogene Ltd from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Evogene (NASDAQ:EVGN) was reported by Lake Street on August 23, 2024. The analyst firm set a price target for $12.00 expecting EVGN to rise to within 12 months (a possible 722.20% upside). 1 analyst firms have reported ratings in the last year.
The latest analyst rating for Evogene (NASDAQ:EVGN) was provided by Lake Street, and Evogene maintained their buy rating.
There is no last upgrade for Evogene
There is no last downgrade for Evogene.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evogene, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evogene was filed on August 23, 2024 so you should expect the next rating to be made available sometime around August 23, 2025.
While ratings are subjective and will change, the latest Evogene (EVGN) rating was a maintained with a price target of $30.00 to $12.00. The current price Evogene (EVGN) is trading at is $1.46, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.